High prevalence rates illustrate the relevance of allergic research
An unmet need for novel targeted medicines that treat the underlying cause of allergic rhinitis and asthma still does exist. Until now allergen immunotherapy is the only disease modifying therapy tackling the cause of allergies. It even can reduce the risk of allergic asthma development. HAL Allergy constantly develops more effective allergen immunotherapies for root cause treatments for respiratory, venom and food allergies.
Science-based innovations for global allergies with significant medical need
HAL Allergy bases its allergen therapeutics on its innovative and science-based research and development.
All of our activities are targeted to provide the best possible medical products and scientific output in order to increase quality of life for allergic patients.
Developing therapeutics for respiratory allergens
Despite modern medicines, still many patients with respiratory allergies and asthma are not adequately controlled or are insufficiently treated with symptomatic therapy. Due to climate change other allergens do come up in other regions and might become a burden in the next years, e.g. ragweed now upcoming in Europe. Further respiratory allergies are a risk of developing asthma. Driven by these developments, HAL Allergy currently tests allergen immunotherapies for respiratory allergies (ragweed and mites) in clinical trials.
Developing therapeutics for food allergies
Food allergies can cause unpredictable and life-threatening anaphylactic reactions. Currently no approved treatment options are available. Even with avoidance of the food causing the allergic reactions, people are not safe. The risk of accidental exposure, via cross-contamination is high. Thus, there is an unmet medical need, which makes the development of safe and effective medicines for food allergy essential. The most promising therapeutic approach for the future is the allergen immunotherapy. Taking the unmet medical need into focus HAL Allergy currently tests allergen immunotherapies for food allergies (peanut and other food related products) in clinical trials.